• C F Waller, M Ali, M Heinzinger, and W Lange.
• Department of Internal Medicine I-Hematology/Oncology-, Albert-Ludwigs-University, Freiburg Medical Center, Germany.
• Anticancer Res. 2000 Mar 1; 20 (2A): 809-14.

BackgroundDifferent methods have been investigated for their purging capacity of contaminating CML cells in autologous stem cell products. CGP57148B, a tyrphostin, has been shown to be efficient in the reduction of cell proliferation of CML cell lines and primary CML cells, as well as in the inhibition of bcr/abl-related tumor formation in animal models.Materials And MethodsThe effect of CGP57148B on purified CD34+ progenitor cells from BM, PB, or leukapheresis products of 8 CML patients was studied under serum-free cytokine-supplemented ex vivo culture conditions.ResultsFISH as well as RT-PCR analysis showed a significant reduction of Ph+ cells after 7 days ex vivo-culture in the presence of the tyrphostin. Growth of Ph- cells was almost unaffected by treatment with CGP57148B.ConclusionOur results support the observation that CGP57148B can selectively inhibit proliferation of Ph+/bcr/abl+ primary CML cells under serum-free cytokine-supplemented culture conditions.

38 keywords...

hide…